Copyright
©The Author(s) 2022.
World J Clin Oncol. Feb 24, 2022; 13(2): 71-100
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.71
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.71
Ref. | Yr | n1 | Design | Treatment | Conclusion |
Dew et al[178] | 2003 | 69 | Retrospective Cohort study | Estriol 0.5 mg cream and pessaries (33); Estradiol 25 μgtablets (n = 33) | VET does not seem to be associated with increased RR of BC |
Kendall et al[190] | 2005 | 7 | Prospective before-after analysis | Estradiol 25 mg daily for 2 wk | Vaginal estradiol tablet significantly raises systemic estradiol levels. This reverses the estradiol suppression achieved by AIs in women with BC and is contraindicated |
Biglia N et al[179] | 2010 | 26 | Prospective study | Estriol cream 0.25 mg (n = 10) or estradiol tablets 12.5 microg (n = 8) polycarbophil-based moisturizer 2.5 g (Replens®) (n = 8) | VET is effective in improving symptoms and objective evaluations in BCSs |
Pfeifer et al[180] | 2011 | 10 | Prospective before-after analysis | 0.5 mg vaginal estriol daily for 2 wk | Increase in FHS and LH may indicate systemic estradiol effects |
Whiterby et al[201] | 2011 | 21 | Phase I/II pilot Before-After study | Testosterone cream daily for 28 d. 300/ 150 μg | Vaginal testosterone was associated with improved signs and symptoms of vaginal atrophy related to AI therapy without increasing estradiol or testosterone levels |
Wills et al[49] | 2012 | 24 vs 24 | Prospective clinical trial | 25 mcg estradiol vaginal tablet or ring vs control | VET treatment increases E2 levels. Should be used with caution |
Le Ray et al[187] | 2012 | 13479TAM (n = 10806) or AIs (n = 2673) | Retrospective, nested case-control study | Vaginal cream and tablets containing estrogen | Use of VET is not associated with increase in BC recurrence in those treated with TMX or AI |
Dahir et al[202] | 2014 | 13 | Pilot before-after study | Testosterone cream daily for 28 d, 300 μg | Improvement in FSFI scores |
Donders et al[181] | 2014 | 16 | Open label bicentric phase I pharmacokinetic study | 0.03 mg Estriol + Lactobacillus | Estriol + Lactobacillusis safe in BCpatients andimprovessymptoms |
Melisko et al[204] | 2016 | 69 | Randomised non-comparative study | Estradiol ring 7.5 ng vs Testosterone cream at 1% concentration: 1.5 mg/wk | Transient increase in E2 that finally reached normal levels. Meets the primary safety endpoint |
Davis et al[203] | 2018 | 44 | Double-blind, randomised, placebo-controlled trial | Testosterone cream daily for 26 week/ 300 μg vs placebo | Testosterone improves sexual test items compared to placebo |
- Citation: Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol 2022; 13(2): 71-100
- URL: https://www.wjgnet.com/2218-4333/full/v13/i2/71.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i2.71